Table 2.
Eradication rates of second-line anti-H. pylori therapies in the randomized controlled trials from 2013 to 2023.
| Type of therapy | Country | Population | Previous treatment | Regimen | Eradication rate | |
|---|---|---|---|---|---|---|
| ITT | PP | |||||
| Standard bismuth quadruple therapy (Tetracycline-metronidazole quadruple therapy) | Taiwan 19 | Adult patients with dyspepsia (n = 74) | Standard triple therapy | Esomeprazole 40 mg bid, bismuth 300 mg qid, tetracycline 500 mg qid, metronidazole 500 mg qid |
80% | 91% |
| Taiwan 21 | Adult patients (n = 261) |
Clarithromycin-based therapy | Esomeprazole 40 mg bid bismuth 300 mg qid tetracycline 500 mg qid metronidazole 500 mg tid for 10 days |
88% | 93% | |
| Israel 22 | Adult patients (n = 51) |
Clarithromycin- triple therapy | Lansoprazole 30 mg bid bismuth 525 mg qid metronidazole 500 mg tid tetracycline 500 mg qid /doxycycline 100 mg bid for 14 days |
43% | 69% | |
| Taiwan 23 | Adult patients (n = 63) |
Standard triple therapy | Rabeprazole 20 mg bid, bismuth 120 mg qid, tetracycline 500 mg qid, metronidazole 250 mg qid for 10 days |
92% | 93% | |
| China 24 | Adult patients with dyspepsia (n = 143) |
Clarithromycin-based triple or quadruple therapy | Lansoprazole 30 mg bid, bismuth 240 mg bid, tetracycline 500 mg qid, metronidazole 400 mg qid for 14 days |
85% | 91% | |
| Fluoroquinolone- amoxicillin Triple therapy |
Taiwan 14 | Adult patients (n = 52) |
Clarithromycin triple, non-bismuth quadruple or bismuth quadruple therapy | Esomeprazole 40 mg bid, amoxicillin 500 mg qid, levofloxacin 500 mg qd for 10 days |
69% | 69% |
| China 26 | Adult patients (n = 89) |
Clarithromycin-based or metronidazole-based triple or bismuth quadruple therapy | Esomeprazole 20 mg bid, amoxicillin 1000 mg bid, antofloxacin 200 mg qd for 14 days |
88% | 91% | |
| China 26 | Adult patients (n = 89) |
Clarithromycin-based or metronidazole-based triple or bismuth quadruple therapy | Esomeprazole 20 mg bid, amoxicillin 1000 mg bid, levofloxacin 500 mg qd for 14 days |
69% | 70% | |
| Taiwan 27 | Adult patients with dyspepsia (n = 34) |
Standard triple therapy | Rabeprazole 20 mg bid, amoxicillin 1000 mg bid, levofloxacin 500 mg qd for 10 days |
68% | 67% | |
| Taiwan 28 | Adult patients (n = 82) |
Standard triple, therapy | Esomeprazole 40 mg bid, amoxicillin 1000 mg bid levofloxacin 500 mg qd, for 10 days |
81% | 82% | |
| Taiwan 30 | Adult patients with chronic gastritis or peptic ulcers (n = 56) |
(not described) | Rabeprazole 20 mg bid, amoxicillin 1000 mg bid levofloxacin 500 mg qd, for 7 days |
79% | 79% | |
| Fluoroquinolone- amoxicillin quadruple therapy |
Taiwan 25 | Adult patients (n = 56) |
Standard triple, non-bismuth quadruple and bismuth quadruple therapies) | Esomeprazole 40 mg bid, bismuth 300 mg qid amoxicillin 1000 mg qid levofloxacin 500 mg qd for 10 days |
69% | 69% |
| Taiwan 27 | Adult patients with dyspepsia (n = 33) |
Standard triple therapy | Rabeprazole 20 mg bid, bismuth 120 mg qid amoxicillin 1000 mg bid levofloxacin 500 mg qd for 10 days |
85% | 84% | |
| Taiwan 30 | Adult patients (n = 300) |
Clarithromcyin-based therapies | Lansoprazole 30 mg bid, amoxicillin 1000 mg bid levofloxacin 500 mg qd, for 10 days |
75% | 79% | |
| China 24 | Adult patients with dyspepsia (n = 141) | Clarithromycin-based triple or quadruple therapy | Lansoprazole 30 mg bid, bismuth 240 mg bid, amoxicillin, 1000 mg bid, levofloxacin 500 mg qd |
83% | 88% | |
| Tetracycline-fluoroquinolone quadruple therapy | Taiwan 19 | Adult patients with dyspepsi a (n = 76) | Standard triple therapy | Esomeprazole 40 mg bid, bismuth 300 mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd for 10 days |
79% | 87% |
| Taiwan 14 | Adult patients (n = 50) |
Standard triple, non-bismuth quadruple and bismuth quadruple therapies | Esomeprazole 40 mg bid, bismuth 300 mg qid tetracycline 500 mg qid levofloxacin 500 mg qd for 10 days |
98% | 98% | |
| Taiwan 25 | Adult patients (n = 56) |
Standard triple, non-bismuth quadruple and bismuth quadruple therapies | Esomeprazole 40 mg bid, bismuth 300 mg qid tetracycline 500 mg qid levofloxacin 500 mg qd for 10 days |
89% | 89% | |
| Turkey 31 | Adult patients with peptic ulcer or non-ulcer dyspepsia (n = 75) |
Standard triple therapy | Pantoprazole 40 mg bid, bismuth 300 mg qid tetracycline 500 mg qid levofloxacin 500 mg qd for 10 days |
91% | 93% | |
| High-dose dual therapy | China 32 | Adult patients (n = 329) |
Standard triple, bismuth-containing quadruple therapy, or non-bismuth quadruple therapy | Esomeprazole 40 mg tid, amoxicillin 1000 mg tid for 14 days |
75% | 81% |
| Taiwan 29 | Adult patients (n = 56) |
(not described) | Rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days |
89% | 89% | |
| Levofloxacin- based sequential quadruple therapy |
Taiwan 21 | Adult patients (n = 280) | Clarithromycin-based therapy | Esomeprazole 40 mg bid and amoxicillin 1000 mg bid for 7 days, then esomeprazole 40 mg bid, metronidazole 500 mg bid, and levofloxacin 250 mg for 7 days, |
88% | 90% |
| Taiwan 28 | adult patients (n = 82) |
standard triple, therapy | esomeprazole 40 mg bid, amoxicillin 1000 mg bid for 5 days, then esomeprazole 40 mg bid, levofloxacin 500 mg qd, metronidazole 500 mg tid for 5 days |
90% | 91% | |
| Taiwan 30 | Adult patients (n = 300) |
Clarithromcyin-based therapies | Lansoprazole 30 mg bid, amoxicillin 1000 mg bid for 5 days, then lansoprazole 30 mg bid, levofloxacin 500 mg qd, metronidazole 500 mg tid for 5 days |
84% | 86% | |
| Turkey 31 | Adult patients with peptic ulcer or non-ulcer dyspepsia (n = 70) | Standard triple therapy | Pantoprazole 40 mg bid, amoxicillin 1000 mg bid for 5 days, then pantoprazole 30 mg bid, levofloxacin 500 mg qd, metronidazole 500 mg tid for 5 days |
82% | 86% | |
| Tetracycline- metronidazole- amoxicillin concomitant therapy |
Taiwan 23 | Adult patients (n = 61) |
Standard triple therapy | Rabeprazole 20 mg bid, amoxicillin 1000 mg bid, tetracycline 500 mg qid, metronidazole 250 mg qid for 10 days |
90% | 89% |
| Furazolidone-tetracycline quadruple therapy | China 32 | Adult patients (n = 329) |
Standard triple, bismuth-containing quadruple therapy, or non-bismuth quadruple therapy | Esomeprazole 40 mg tid, bismuth 220 mg bid, furazolidone 100 mg bid, tetracycline 500 mg tid for 14 days |
78% | 85% |
| Amoxicillin-clarithromycin-metronidazole quintuple therapy |
Iran 33 | Adult patients with dyspepsia (n = 104) |
Non-bismuth quadruple therapy | Omeprazole 20 mg bid, bismuth 240 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid, tinidazole 500 mg bid for 7 days |
76% | 76% |
| Tetracycline- metronidazole- ofloxacin quintuple therapy |
Iran 33 | Adult patients with dyspepsia (n = 104) |
Non-bismuth quadruple therapy | Omeprazole 20 mg bid, bismuth 240 mg bid, tetracycline 500 mg qid, metronidazole 500 mg bid, ofloxacin 200 mg bid for 7 days |
87% | 87% |
ITT, intention-to-treat; PP, per-protocol.